Chen Y, Willmott N, Anderson J, Florence A T
Department of Pharmacy, School of Pharmaceutical Sciences, University of Strathclyde, Glasgow, UK.
J Pharm Pharmacol. 1987 Dec;39(12):978-85. doi: 10.1111/j.2042-7158.1987.tb03144.x.
Doxorubicin (Adriamycin)-loaded casein and albumin microspheres, with diameters between 14 and 38 micron (50% weight average) were prepared by glutaraldehyde stabilization of the aqueous phase (containing protein and drug) of a water in oil emulsion. Physical properties, drug loading characteristics and release rates from microspheres in-vitro have been compared and correlated with effects on tumour growth when injected intratumourally in rats. Compared with albumin, the surface charge of the casein system was more negative and the microspheres exhibited a slower release of drug in-vitro. Both observations could be explained by the lower drug content of the casein system. There was evidence for the formation of a doxorubicin complex in the microspheres, the significance of which is not yet known. Casein microspheres containing 11 micrograms of doxorubicin had a similar inhibitory effect on tumour growth (growth delay = 20.7 days) to 85 micrograms of drug incorporated into albumin microspheres (growth delay = 18.6 days). The absence of a simple dose-response relationship shows that carrier matrix can influence potency of incorporated drug. The results are consistent with release rate of the drug from microspheres (obversely, rate of drug delivery to the tumour), being a determinant of potency in these systems.
通过对油包水乳液的水相(含蛋白质和药物)进行戊二醛固化,制备了直径在14至38微米之间(重量平均直径为50%)的载有阿霉素(阿德里亚霉素)的酪蛋白和白蛋白微球。已对微球的物理性质、载药特性和体外释放速率进行了比较,并将其与大鼠瘤内注射后对肿瘤生长的影响相关联。与白蛋白相比,酪蛋白体系的表面电荷更负,且微球在体外表现出较慢的药物释放。这两种现象都可以用酪蛋白体系中较低的药物含量来解释。有证据表明微球中形成了阿霉素复合物,但其意义尚不清楚。含有11微克阿霉素的酪蛋白微球对肿瘤生长的抑制作用(生长延迟 = 20.7天)与掺入白蛋白微球中的85微克药物相似(生长延迟 = 18.6天)。不存在简单的剂量反应关系表明载体基质可影响掺入药物的效力。结果表明,药物从微球中的释放速率(相反,药物向肿瘤的递送速率)是这些体系中效力的决定因素,这一结果与之相符。